Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms

BACKGROUND: Dual checkpoint inhibitor therapy with anti-programmed cell death protein 1 and anti-cytotoxic T-lymphocyte-associated protein 4 therapy has shown promising results in patients with high-grade neuroendocrine neoplasms (NENs), demonstrating varying response rates of 9%-44%. More data are...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Toubah, T., Halfdanarson, T., Gile, J., Morse, B., Sommerer, K., Strosberg, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728436/
https://www.ncbi.nlm.nih.gov/pubmed/34973511
http://dx.doi.org/10.1016/j.esmoop.2021.100364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728436/
https://www.ncbi.nlm.nih.gov/pubmed/34973511
http://dx.doi.org/10.1016/j.esmoop.2021.100364

Ejemplares similares